Login to Your Account

That's a 'Loxo' cash: $120M offering to accelerate larotrectinib prospects

By Marie Powers
News Editor

Thursday, January 5, 2017

Loxo Oncology Inc. is seeking to raise approximately $120 million through an underwritten public offering of 3.87 million common shares priced at $31 apiece, a discount of about 5 percent from Wednesday's close of $32.69 for the company's shares (NASDAQ:LOXO).

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription